To this end, adding anti-PD-L1 to RT significantly boosted overall efficacy and enhanced anti-tumor immunity, including increased production of IFN-γ in pancreatic ductal adenocarcinoma [147] and hepatocellular carcinoma [148]. The gene discussed is IFNG; the disease is neoplasm.